FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 355:1054-1055 September 7, 2006 Number 10 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Olaussen, K. A. PubMed Citation

Clinical oncology has struggled for decades with the predicament of the toxicity of chemotherapy for the treatment of malignant disease. For example, cisplatin and its analogues, carboplatin and oxaliplatin, are commonly used anticancer agents, but they are particularly toxic. Moreover, some patients benefit substantially from treatment with these drugs, whereas others suffer the toxic effects of the drugs without obtaining real benefit. The use of molecular markers to help identify who may benefit and who may not is one of the most exciting new areas of study in oncology.

The randomized International Adjuvant Lung Cancer Trial (IALT) found a modest . . . [Full Text of this Article]

Source Information

From the Division of Cancer Prevention and Control, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta.

This article has been cited by other articles:

• Gao, R., Price, D. K., Sissung, T., Reed, E., Figg, W. D. (2008). Ethnic disparities in Americans of European descent versus Americans of African descent related to polymorphic ERCC1, ERCC2, XRCC1, and PARP1. Molecular Cancer Therapeutics 7: 1246-1250 [Abstract] [Full Text]  
• Darcy, K. M., Tian, C., Reed, E. (2007). A Gynecologic Oncology Group Study of Platinum-DNA Adducts and Excision Repair Cross-Complementation Group 1 Expression in Optimal, Stage III Epithelial Ovarian Cancer Treated with Platinum-Taxane Chemotherapy. Cancer Res. 67: 4474-4481 [Abstract] [Full Text]  
• Gazdar, A. F. (2007). DNA Repair and Survival in Lung Cancer -- The Two Faces of Janus. NEJM 356: 771-773 [Full Text]